Reviva Pharmaceuticals (RVPH) Stock Forecast, Price Target & Predictions

RVPH Stock Forecast

Reviva Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

RVPH Analyst Ratings

Buy

According to 2 Wall Street analysts, Reviva Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RVPH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 23, 2024	EF Hutton		Buy	Initialise
Jun 11, 2024	H.C. Wainwright	Buy	Buy	Hold
Jan 24, 2022	H.C. Wainwright		Buy	Initialise

Reviva Pharmaceuticals's last stock rating was published by EF Hutton on Sep 23, 2024. The company Initialise its RVPH rating from "null" to "Buy".

Reviva Pharmaceuticals Financial Forecast

Reviva Pharmaceuticals Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$48.29M	$46.44M	$46.44M	$44.58M	-	-	-	-	-	-	-	-	-	-
High Forecast	$48.29M	$46.44M	$46.44M	$44.58M	-	-	-	-	-	-	-	-	-	-
Low Forecast	$48.29M	$46.44M	$46.44M	$44.58M	-	-	-	-	-	-	-	-	-	-
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Reviva Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RVPH's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Reviva Pharmaceuticals EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-10.61M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict RVPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Reviva Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Reviva Pharmaceuticals Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-10.49M
Avg Forecast	-	-	-	-	$-9.13M	$-8.11M	$-8.11M	$-8.11M	$-7.89M	$-8.25M	$-7.26M	$-9.05M	$-7.87M	$-8.57M
High Forecast	-	-	-	-	$-9.13M	$-8.11M	$-8.11M	$-8.11M	$-7.26M	$-8.25M	$-7.26M	$-9.05M	$-5.34M	$-8.57M
Low Forecast	-	-	-	-	$-9.13M	$-8.11M	$-8.11M	$-8.11M	$-8.20M	$-8.25M	$-7.26M	$-9.05M	$-10.40M	$-8.57M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.22%

Reviva Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RVPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Reviva Pharmaceuticals SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.99M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Reviva Pharmaceuticals's average Quarter SG&A projection for Dec 23 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RVPH last annual SG&A of $1.99M (Sep 23).

Reviva Pharmaceuticals EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.44
Avg Forecast	-	-	-	-	$-0.27	$-0.24	$-0.24	$-0.24	$-0.23	$-0.24	$-0.30	$-0.38	$-0.33	$-0.36
High Forecast	-	-	-	-	$-0.27	$-0.24	$-0.24	$-0.24	$-0.21	$-0.24	$-0.30	$-0.38	$-0.22	$-0.36
Low Forecast	-	-	-	-	$-0.27	$-0.24	$-0.24	$-0.24	$-0.24	$-0.24	$-0.30	$-0.38	$-0.43	$-0.36
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.23%

According to undefined Wall Street analysts, Reviva Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RVPH previous annual EPS of $NaN (undefined).

Reviva Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INAB	IN8bio	$0.29	$14.00	4727.59%	Buy
ATHA	Athira Pharma	$0.59	$18.00	2950.85%	Buy
RVPH	Reviva Pharmaceuticals	$1.40	$10.00	614.29%	Buy
CABA	Cabaletta Bio	$2.75	$16.33	493.82%	Buy
SLS	SELLAS Life Sciences Group	$0.88	$2.80	218.18%	Buy
CUE	Cue Biopharma	$1.06	$3.00	183.02%	Buy
EYPT	EyePoint Pharmaceuticals	$8.02	$22.00	174.31%	Buy
ACAD	ACADIA Pharmaceuticals	$17.41	$25.50	46.47%	Buy

RVPH Forecast FAQ

Is Reviva Pharmaceuticals a good buy?

Yes, according to 2 Wall Street analysts, Reviva Pharmaceuticals (RVPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of RVPH's total ratings.

What are Reviva Pharmaceuticals's analysts' financial forecasts?

Reviva Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-33.467M (high $-33.467M, low $-33.467M), average SG&A $0 (high $0, low $0), and average EPS is $-0.99 (high $-0.99, low $-0.99). RVPH's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $185.75M (high $185.75M, low $185.75M), average EBITDA is $0 (high $0, low $0), average net income is $0 (high $0, low $0), average SG&A $0 (high $0, low $0), and average EPS is $0 (high $0, low $0).